Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Therapeutic inertia in type 2 diabetes mellitus: a fine line between advancing and de-intensifying

Nature Reviews Endocrinology volume 19, pages 437–438 (2023)Cite this article

Subjects

Type 2 diabetes mellitus is a progressive disease requiring regular monitoring and therapeutic changes. It is important that healthcare professionals embrace both ends of the spectrum of therapeutic inertia, including appropriate advancement and de-intensification of therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overcoming therapeutic inertia over the life course of a person with T2DM.

References

  1. Khunti, K., Kosiborod, M. & Ray, K. K. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia? Diabetes Obes. Metab. 20, 1337–1341 (2018).

    Article  PubMed  Google Scholar 

  2. Mauricio, D. et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes. Metab. 19, 1155–1164 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Khunti, K., Ceriello, A., Cos, X. & De Block, C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 137, 137–148 (2018).

    Article  PubMed  Google Scholar 

  4. Khunti, S., Khunti, K. & Seidu, S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther. Adv. Endocrinol. Metab. 10, 2042018819844694 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Khunti, K. & Aroda, V. R. Coming full circle: prioritizing early glycemic control to reduce microvascular and macrovascular complications in people with type 2 diabetes. Diabetes Care 45, 766–768 (2022).

    Article  PubMed  Google Scholar 

  6. Wrzal, P. K. et al. Strategies to overcome therapeutic inertia in type 2 diabetes mellitus: a scoping review. Can. J. Diabetes 45, 273–281.e13 (2021).

    Article  PubMed  Google Scholar 

  7. Powell, R. E. et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes. Metab. 23, 2137–2154 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Bain, S. C., Bekker Hansen, B., Hunt, B., Chubb, B. & Valentine, W. J. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J. Med. Econ. 23, 98–105 (2020).

    Article  PubMed  Google Scholar 

  9. Ali, S. N., Dang-Tan, T., Valentine, W. J. & Hansen, B. B. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. Adv. Ther. 37, 869–882 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Seidu, S. et al. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes. Metab. 21, 1668–1679 (2019).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

K.K. acknowledges the support of the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands and the NIHR Leicester Biomedical Research Centre.

Author information

Authors and Affiliations

  1. Diabetes Research Centre, University of Leicester, Leicester, UK

    Kamlesh Khunti

  2. Trillium Health Partners and Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada

    Alice Y. Y. Cheng

Authors
  1. Kamlesh Khunti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice Y. Y. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kamlesh Khunti.

Ethics declarations

Competing interests

K.K. has acted as a consultant, speaker or received grants for investigator-initiated studies for Astra Zeneca, Bayer, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Roche and Applied Therapeutics. K.K. is chair of the American Diabetes Association Therapeutic Inertia Initiative. A.Y.Y.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khunti, K., Cheng, A.Y.Y. Therapeutic inertia in type 2 diabetes mellitus: a fine line between advancing and de-intensifying. Nat Rev Endocrinol 19, 437–438 (2023). https://doi.org/10.1038/s41574-023-00857-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-023-00857-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing